BioSpace News Archive

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), today reported financial results for the third quarter and nine months ended September 30, 2021, and highlighted recent corporate progress.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2021.

Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced its financial results for the third quarter ended September 30, 2021.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced financial results for the third quarter ended September 30, 2021, and provided a business update.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference.

Rani Therapeutics (NASDAQ: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, at 7:00 a.m. PT / 10:00 a.m. ET.

Ascendis Pharma A/S (Nasdaq: ASND), today announced financial results for the third quarter ended September 30, 2021.

Dyadic International, Inc., a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for the third quarter of 2021, and highlighted recent Company progress.

Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, reported financial results for the third quarter ended September 30, 2021 and provided an update on its corporate activities and product pipeline.